W
William J. Gradishar
Researcher at Northwestern University
Publications - 42
Citations - 4694
William J. Gradishar is an academic researcher from Northwestern University. The author has contributed to research in topics: Breast cancer & Chemotherapy. The author has an hindex of 22, co-authored 42 publications receiving 4544 citations. Previous affiliations of William J. Gradishar include Stanford University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron,Donald A. Berry,Constance Cirrincione,Clifford A. Hudis,Eric P. Winer,William J. Gradishar,Nancy E. Davidson,Silvana Martino,Robert B. Livingston,James N. Ingle,Edith A. Perez,John T. Carpenter,David D. Hurd,James F. Holland,Barbara L. Smith,Carolyn I. Sartor,Eleanor H. Leung,Jeffrey S. Abrams,Richard L. Schilsky,Hyman B. Muss,Larry Norton +20 more
TL;DR: Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy.
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: A randomized clinical trial to test the hypothesis that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer and the clinical implications.
Journal ArticleDOI
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Martee L. Hensley,Lynn M. Schuchter,Celeste Lindley,Neal J. Meropol,Gary I. Cohen,Gail Broder,William J. Gradishar,Daniel M. Green,Robert J. Langdon,R. Brian Mitchell,Robert S. Negrin,Ted P. Szatrowski,J. Tate Thigpen,Daniel D. VonHoff,Todd H. Wasserman,Eric P. Winer,David G. Pfister +16 more
TL;DR: Evidence-based, clinical practice guidelines for the use of dexrazoxane, mesna, and amifostine in patients who are not enrolled on clinical treatment trials are established and placed the greatest value on lesser toxicity that did not carry a concomitant risk of tumor protection.
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections, and in the total number of days of treatment with intravenous antibiotics and days of hospitalization.
Journal ArticleDOI
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
Martin S. Tallman,Robert Gray,Nicholas J. Robert,Charles F. LeMaistre,C. Kent Osborne,William P. Vaughan,William J. Gradishar,Thomas M. Pisansky,John H. Fetting,Elisabeth Paietta,Hillard M. Lazarus +10 more
TL;DR: In this article, the authors randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjUvant chemotherapy followed by high-dose chemotherapy with Cyprodrugs and thiotepa and autologous hematopoietic stem-cell transplantation, and there was no significant difference in disease-free survival, overall survival, or the time